Dyne Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
DYN$17.92-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development | $44,539 | $37,536 |
| General and administrative | 24,618 | 7,928 |
| Total operating expenses | 69,157 | 45,464 |
| Loss from operations | (69,157) | (45,464) |
| Other income (expense): | ||
| Interest income | 3,002 | 1,493 |
| Other income (expense), net | 506 | (216) |
| Total other income (expense), net | 3,508 | 1,277 |
| Net loss | $(65,649) | $(44,187) |
| Net loss per share—basic and diluted | $(0.81) | $(0.78) |
| Weighted average common shares outstanding, basic and diluted | 81,043,741 | 56,325,864 |
| Comprehensive loss: | ||
| Net loss | $(65,649) | $(44,187) |
| Other comprehensive loss: | ||
| Unrealized (losses) gains on marketable securities, net | (132) | 368 |
| Comprehensive loss | $(65,781) | $(43,819) |
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
(in thousands, except share data and issuance costs)
| Common Stock · AdditionalPaid-In · AccumulatedOther · Accumulated · Stockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Comprehensive Loss | Deficit | Equity | |
| Balance at January 1, 2024 | 61,468,743 | $6 | $723,796 | $— | $(632,510) | $91,292 |
| Issuance of common stock in public offering, net of issuance costs of $21.3 million | 19,722,500 | 2 | 323,849 | — | — | 323,851 |
| Issuance of common stock in at-the-market offering, net of issuance costs of $3.3 million | 3,800,465 | 1 | 97,870 | — | — | 97,871 |
| Exercise of stock options | 1,858,791 | — | 10,916 | — | — | 10,916 |
| Stock-based compensation | — | — | 19,906 | — | — | 19,906 |
| Vesting of restricted stock units | 239,150 | — | — | — | — | — |
| Unrealized losses on marketable securities | — | — | — | (132) | — | (132) |
| Net loss | — | — | — | — | (65,649) | (65,649) |
| Balance at March 31, 2024 | 87,089,649 | $9 | $1,176,337 | $(132) | $(698,159) | $478,055 |
| Common Stock · AdditionalPaid-In · AccumulatedOther · Accumulated · Stockholders’ | ||||||
| (in thousands, except per share data) | Shares | Amount | Capital | Comprehensive Loss | Deficit | Equity |
| Balance at January 1, 2023 | 55,636,505 | $6 | $649,502 | $(571) | $(396,573) | $252,364 |
| Issuance of common stock in public offering, net of issuance costs of $1.0 million | 2,335,150 | — | 28,186 | — | — | 28,186 |
| Exercise of stock options | 232,292 | — | 587 | — | — | 587 |
| Stock-based compensation | — | — | 4,617 | — | — | 4,617 |
| Vesting of restricted stock units | 101,533 | — | — | — | — | — |
| Unrealized gains on marketable securities | — | — | — | 368 | — | 368 |
| Net loss | — | — | — | — | (44,187) | (44,187) |
| Balance at March 31, 2023 | 58,305,480 | $6 | $682,892 | $(203) | $(440,760) | $241,935 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.